By Paul Sandle LONDON (Reuters) - British pharmaceutical company BTG announced two deals on Thursday that it said could create an interventional medicine business with potential sales of $1 billion. Chief Executive Louise Makin told Reuters the deals would more than double BTG's revenues in the fast-growing market of targeting specific areas rather than administering drugs to the whole body. BTG added to its liver cancer treatments by agreeing to buy the targeted therapies division of Nordion Inc for about $200 million, adding Therasphere radioactive glass beads to its chemotherapy beads unit. ... For complete story, click here.
No comments:
Post a Comment